Matches in Nanopublications for { ?s ?p "[Taken together our data suggests that EBBP acts to de-repress transcription of RARbeta2 and CYP26A1, by modifying histone acetylation in retinoid-resistant cancer cells, and, is an important target for drug discovery in retinoid-resistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP632505.RAkvScfifKmiR4tgZvBhJZCEFUdgM036DjOjlkjdanSlQ130_assertion description "[Taken together our data suggests that EBBP acts to de-repress transcription of RARbeta2 and CYP26A1, by modifying histone acetylation in retinoid-resistant cancer cells, and, is an important target for drug discovery in retinoid-resistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632505.RAkvScfifKmiR4tgZvBhJZCEFUdgM036DjOjlkjdanSlQ130_provenance.
- NP711430.RAKtQ_A4VSPlxRgBPS9YB7-rRMBSXhXCua2CZuYDUpIM4130_assertion description "[Taken together our data suggests that EBBP acts to de-repress transcription of RARbeta2 and CYP26A1, by modifying histone acetylation in retinoid-resistant cancer cells, and, is an important target for drug discovery in retinoid-resistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP711430.RAKtQ_A4VSPlxRgBPS9YB7-rRMBSXhXCua2CZuYDUpIM4130_provenance.
- NP848971.RAtR7JEp2TfAo5-OZw1yB2ibhtvlGLKHo-lI6V1LNhZBU130_assertion description "[Taken together our data suggests that EBBP acts to de-repress transcription of RARbeta2 and CYP26A1, by modifying histone acetylation in retinoid-resistant cancer cells, and, is an important target for drug discovery in retinoid-resistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP848971.RAtR7JEp2TfAo5-OZw1yB2ibhtvlGLKHo-lI6V1LNhZBU130_provenance.
- NP345609.RA_r7xqW-DyDULCijDQnmOlPjFU42DCCAq0xdKKKIkkHE130_assertion description "[Taken together our data suggests that EBBP acts to de-repress transcription of RARbeta2 and CYP26A1, by modifying histone acetylation in retinoid-resistant cancer cells, and, is an important target for drug discovery in retinoid-resistant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP345609.RA_r7xqW-DyDULCijDQnmOlPjFU42DCCAq0xdKKKIkkHE130_provenance.